{"id":950766,"date":"2026-04-13T08:33:04","date_gmt":"2026-04-13T12:33:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/"},"modified":"2026-04-13T08:33:04","modified_gmt":"2026-04-13T12:33:04","slug":"tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/","title":{"rendered":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care<\/b><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an &#8220;active follow-up&#8221; track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus\u2019 secure, AI-enabled physician portal.<\/p>\n<p>\nBecause NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient\u2019s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge\u2014all without requiring a new patient sample. This ensures that patient insights remain as current as the science, supporting evidence-based decision-making throughout the patient\u2019s treatment journey.<\/p>\n<p>\n&#8220;The reality in modern oncology practice is that drugs are getting approved and treatments are changing at a much faster rate than before,\u201d said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. \u201cMany times, this creates a situation where a patient&#8217;s tumor harbors a targetable alteration but the treatment gets approved after sequencing is performed. We launched this automated clinical update service with the goal of bridging the gap between timing of sequencing and drug approval by providing a clinical safety net that keeps pace with the speed of medical innovation. By moving to a model of \u2018active follow-up,\u2019 we ensure that genomic insights remain a living resource rather than a static report.\u201d<\/p>\n<p><b>About Tempus<\/b><\/p>\n<p>\nTempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world\u2019s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Ftempus.com&amp;esheet=54491359&amp;newsitemid=20260413202774&amp;lan=en-US&amp;anchor=tempus.com&amp;index=1&amp;md5=b6966e2df2303207f2587ba0c826235b\">tempus.com<\/a>.<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus\u2019 industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding its clinical testing and therapy update services . In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoing to,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.<\/p>\n<p>\nYou should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus\u2019 business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus\u2019 financial performance; the ability to attract and retain customers and partners; managing Tempus\u2019 growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus\u2019 intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled \u201cRisk Factors\u201d in Tempus\u2019 Quarterly Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (\u201cSEC\u201d) on February 24, 2026 as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260413202774\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260413202774\/en\/<\/a><\/span><\/p>\n<p><b>Tempus<br \/>\n<\/b><br \/><b>Hanah Heintzelman<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:hanah.heintzelman@tempus.com\"><b>hanah.heintzelman@tempus.com<\/b><\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Technology Health Technology Practice Management General Health Artificial Intelligence<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260413202774\/en\/566718\/3\/black_wordmark.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an &#8220;active follow-up&#8221; track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus\u2019 secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient\u2019s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge\u2014all &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950766","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an &#8220;active follow-up&#8221; track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus\u2019 secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient\u2019s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge\u2014all &hellip; Continue reading &quot;Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:33:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care\",\"datePublished\":\"2026-04-13T12:33:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/\"},\"wordCount\":830,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/\",\"name\":\"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-13T12:33:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/","og_locale":"en_US","og_type":"article","og_title":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk","og_description":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an &#8220;active follow-up&#8221; track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus\u2019 secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient\u2019s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge\u2014all &hellip; Continue reading \"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-13T12:33:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care","datePublished":"2026-04-13T12:33:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/"},"wordCount":830,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/","name":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-13T12:33:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260413202774r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempus Launches Automated \u201cActive Follow-Up\u201d Service to Support Guideline-Concordant Care"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950766"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950766\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}